Fenfluramine evokes 5-HT2A receptor-mediated responses but does not displace [11C]MDL 100907: small animal PET and gene expression studies.

Fenfluramine evokes 5-HT2A receptor-mediated responses but does not displace [11C]MDL 100907: small animal PET and gene expression studies.

The in vivo binding of the 5-HT(2A) receptor-selective positron emission tomography (PET) ligand [(11)C]MDL 100907 and its sensitivity to endogenous 5-HT were quantified in rat brain using quad-HIDAC, a novel high-resolution PET camera for small animals. Specific binding of [(11)C]MDL 100907, estima...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Hirani, E, Sharp, T, Sprakes, M, Grasby, P, Hume, S
Formato:	Journal article
Idioma:	English
Publicado em:	2003

Registros relacionados

Effect of endogenous 5-HT on [C-11]MDL 100907 binding investigated in rat brain using PET
por: Hirani, E, et al.
Publicado em: (2003)

Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses.
por: Meyer, P, et al.
Publicado em: (2010)

Validation of a tracer kinetic model for the quantification of 5-HT(2A) receptors in human brain with [(11)C]MDL 100,907.
por: Hinz, R, et al.
Publicado em: (2007)

Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907.
por: Bhagwagar, Z, et al.
Publicado em: (2006)

Can we measure 5-HT release with PET?
por: Grasby, P, et al.
Publicado em: (2003)

p-Chloroamphetamine (PCA), 3,4-methylenedioxy-methamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo.
por: Series, H, et al.
Publicado em: (1994)

Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation
por: Frederick S. Barrett, et al.
Publicado em: (2022-01-01)

EFFECT OF AMINO-ACID LOADS ON HIPPOCAMPAL 5-HT RELEASE INVITRO EVOKED BY ELECTRICAL-STIMULATION OF THE DORSAL RAPHE NUCLEUS AND D-FENFLURAMINE ADMINISTRATION
por: Gartside, S, et al.
Publicado em: (1992)

Pre- and postsynaptic serotonergic differences in males with extreme levels of impulsive aggression without callous unemotional traits: a positron emission tomography study using (11)C-DASB and (11)C-MDL100907.
por: Rylands, A, et al.
Publicado em: (2012)

Tyrosine-free amino acid mixture attenuates amphetamine-induced displacement of [11C]raclopride in striatum in vivo: a rat PET study.
por: Le Masurier, M, et al.
Publicado em: (2004)

Pindolol occupancy of 5-HT(1A) receptors measured in vivo using small animal positron emission tomography with carbon-11 labeled WAY 100635.
por: Hirani, E, et al.
Publicado em: (2000)

The 5-HT2A receptor antagonist M100907 produces antiparkinsonian effects and decreases striatal glutamate
por: Twum eAnsah, et al.
Publicado em: (2011-06-01)

IN-VIVO EVIDENCE THAT D-FENFLURAMINE RELEASES 5-HT FROM NERVE-TERMINALS OF BOTH THE DORSAL AND MEDIAN RAPHE NUCLEI
por: Mcquade, R, et al.
Publicado em: (1995)

5-HT neuroendocrine function in major depression: prolactin and cortisol responses to D-fenfluramine.
por: Park, S, et al.
Publicado em: (1996)

Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine.
por: Fineberg, N, et al.
Publicado em: (1997)

ANTAGONIST EFFECT OF MDL-73005EF ON POSTSYNAPTIC 5-HT1A RECEPTORS IN THE RAT
por: Gartside, S, et al.
Publicado em: (1990)

Fenfluramine: a plethora of mechanisms?
por: Jo Sourbron, et al.
Publicado em: (2023-05-01)

The MDL Programming Language
por: Galley, S.W., et al.
Publicado em: (2023)

The MDL Programming Environment
por: Lebling, P. David
Publicado em: (2023)

A tyrosine-free amino acid mixture attenuates amphetamine-induced displacement of [C-11]raclopride inistriatum: A rat PET study
por: Le Masurier, M, et al.
Publicado em: (2003)

[11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS.
por: Turner, M, et al.
Publicado em: (2005)

The anorexic effect of DL-fenfluramine is dependent on animals' habituation to different food types
por: Sun Shin Yi, et al.
Publicado em: (2022-11-01)

Glutamate receptor activation is involved in 5-HT2 agonist-induced Arc gene expression in the rat cortex.
por: Pei, Q, et al.
Publicado em: (2004)

Fenfluramine Add-On Therapy of Dravet Syndrome
por: J Gordon Millichap
Publicado em: (2012-08-01)

Effects of MDL 73005EF on central pre- and postsynaptic 5-HT1A receptor function in the rat in vivo.
por: Gartside, SE, et al.
Publicado em: (1990)

The MDL Programming Language Primer
por: Dornbrook, Michael, et al.
Publicado em: (2023)

Effect of pindolol on the prolactin response to d-fenfluramine.
por: Park, S, et al.
Publicado em: (1995)

Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine
por: Gianluca Dini, et al.
Publicado em: (2022-05-01)

5-HT1A receptor binding in panic disorder; comparison with depressive disorder and healthy volunteers using PET and [11C]WAY-100635
por: Sargent, P, et al.
Publicado em: (2000)

A Dynamic Debugging System for MDL
por: Berez, Joel M.
Publicado em: (2023)

Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635.
por: Rabiner, E, et al.
Publicado em: (2000)

In vivo evidence that 5-HT(2C) receptors inhibit 5-HT neuronal activity via a GABAergic mechanism.
por: Boothman, L, et al.
Publicado em: (2006)

Effect of paroxetine in combination with the 5-HT1A antagonists, NAD-299 and LY 426965, on expression of the immediate early gene arc in the rat brain
por: Tordera, R, et al.
Publicado em: (2002)

Stimulation by fenfluramine of glucose uptake into skeletal muscle in vitro.
por: Frayn, K, et al.
Publicado em: (1974)

THE EFFECTS OF DIETING ON D-FENFLURAMINE INDUCED PROLACTIN RESPONSE
por: Walsh, A, et al.
Publicado em: (1993)

Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine
por: Gianluca Dini, et al.
Publicado em: (2023-01-01)

A review of fenfluramine for the treatment of Dravet syndrome patients
por: Kayla Simon, et al.
Publicado em: (2022-01-01)

Risk of valvular heart disease associated with use of fenfluramine
por: Polukoff Gerald I, et al.
Publicado em: (2003-06-01)

In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions
por: Parthena Martin, et al.
Publicado em: (2022-06-01)

A device-independent graphics manager for MDL
por: Lim, Poh Chuan
Publicado em: (2016)